drugset / Trial / NCT07526974
A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 )
RandomizedParallel-groupTriple-blindTreatment
Summary
A phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat.
Timeline
- Start
- 2026-10
- Primary completion
- 2027-08
- Completion
- 2027-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CBL-514 | Unknown | 120 ml | Subcutaneous |
Indications
No indication recorded.